All Stories

  1. Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemia

    Article • Cancer and Metastasis Reviews, August 2024, Springer Science + Business Media

    Kate Vandyke

  2. Mesenchymal stromal cell senescence in haematological malignancies

    Article • Cancer and Metastasis Reviews, January 2023, Springer Science + Business Media

    Kate Vandyke

  3. Seed and soil revisited in multiple myeloma

    Article • Blood, April 2021, American Society of Hematology

    Kate Vandyke

  4. Macrophages in multiple myeloma: key roles and therapeutic strategies

    Article • Cancer and Metastasis Reviews, January 2021, Springer Science + Business Media

    Kate Vandyke

  5. Tumour Dissemination in Multiple Myeloma Disease Progression and Relapse: A Potential Therapeutic Target in High-Risk Myeloma

    Article • Cancers, December 2020, MDPI AG

    Kate Vandyke

  6. Targeted Disruption of Bone Marrow Stromal Cell-Derived Gremlin1 Limits Multiple Myeloma Disease Progression In Vivo

    Article • Cancers, August 2020, MDPI AG

    Kate Vandyke

  7. LCRF‐0006, a small molecule mimetic of the N‐cadherin antagonist peptide ADH‐1, synergistically increases multiple myeloma response to bortezomib

    Article • FASEB BioAdvances, June 2020, Wiley

    Kate Vandyke

  8. Twist-1 is upregulated by NSD2 and contributes to tumour dissemination and an epithelial-mesenchymal transition-like gene expression signature in t(4;14)-positive multiple myeloma

    Article • Cancer Letters, April 2020, Elsevier

    Kate Vandyke

  9. GLIPR1 expression is reduced in multiple myeloma but is not a tumour suppressor in mice

    Article • PLOS One, January 2020, PLOS

    Kate Vandyke

  10. Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo

    Article • Neoplasia, August 2019, Elsevier

    Kate Vandyke

  11. A niche-dependent myeloid transcriptome signature defines dormant myeloma cells

    Article • Blood, July 2019, American Society of Hematology

    Kate Vandyke, Dr Natasa Kovacic

  12. N-cadherin in cancer metastasis, its emerging role in haematological malignancies and potential as a therapeutic target in cancer

    Article • BMC Cancer, October 2018, Springer Science + Business Media

    Kate Vandyke

  13. DNA Barcoding Reveals Habitual Clonal Dominance of Myeloma Plasma Cells in the Bone Marrow Microenvironment

    Article • Neoplasia, December 2017, Elsevier

    Kate Vandyke

  14. HIF-2α Promotes Dissemination of Plasma Cells in Multiple Myeloma by Regulating CXCL12/CXCR4 and CCR1

    Article • Cancer Research, August 2017, American Association for Cancer Research (AACR)

    Kate Vandyke

  15. Sphingosine kinase 2 inhibition synergises with bortezomib to target myeloma by enhancing endoplasmic reticulum stress

    Article • Oncotarget, April 2017, Impact Journals, LLC

    Kate Vandyke

  16. The cationic small molecule GW4869 is cytotoxic to high phosphatidylserine-expressing myeloma cells

    Article • British Journal of Haematology, February 2017, Wiley

    Kate Vandyke

  17. EZH2 deletion in early mesenchyme compromises postnatal bone microarchitecture and structural integrity and accelerates remodeling

    Article • The FASEB Journal, December 2016, Federation of American Societies For Experimental Biology (FASEB)

    Kate Vandyke, John Codrington

  18. Identification of Novel EZH2 Targets Regulating Osteogenic Differentiation in Mesenchymal Stem Cells

    Article • Stem Cells and Development, June 2016, Mary Ann Liebert Inc

    Kate Vandyke

  19. Immunomodulatory Properties of Induced Pluripotent Stem Cell-Derived Mesenchymal Cells

    Article • Journal of Cellular Biochemistry, June 2016, Wiley

    Kate Vandyke

  20. PTTG1 expression is associated with hyperproliferative disease and poor prognosis in multiple myeloma

    Article • Journal of Hematology & Oncology, October 2015, Springer Science + Business Media

    Kate Vandyke

  21. Therapeutic targeting of N-cadherin is an effective treatment for multiple myeloma

    Article • British Journal of Haematology, July 2015, Wiley

    Kate Vandyke

  22. Tetraspanin 7 (TSPAN7) expression is upregulated in multiple myeloma patients and inhibits myeloma tumour development in vivo

    Article • Experimental Cell Research, March 2015, Elsevier

    Kate Vandyke

  23. The effect of the dual PI3K and mTOR inhibitor BEZ235 on tumour growth and osteolytic bone disease in multiple myeloma

    Article • European Journal Of Haematology, September 2014, Wiley

    Kate Vandyke

  24. SAMSN1 Is a Tumor Suppressor Gene in Multiple Myeloma

    Article • Neoplasia, July 2014, Elsevier

    Kate Vandyke

  25. Engineering Interaction between Bone Marrow Derived Endothelial Cells and Electrospun Surfaces for Artificial Vascular Graft Applications

    Article • Biomacromolecules, March 2014, American Chemical Society (ACS)

    Kate Vandyke

  26. EphB4 enhances the process of endochondral ossification and inhibits remodeling during bone fracture repair

    Article • Journal of Bone and Mineral Research, March 2013, Wiley

    Natalie A Sims, Kate Vandyke

  27. Circulating N-cadherin levels are a negative prognostic indicator in patients with multiple myeloma

    Article • British Journal of Haematology, February 2013, Wiley

    Kate Vandyke

  28. Prospective Histomorphometric and DXA Evaluation of Bone Remodeling in Imatinib-Treated CML Patients: Evidence for Site-Specific Skeletal Effects

    Article • The Journal of Clinical Endocrinology & Metabolism, January 2013, Endocrine Society

    Natalie A Sims, Kate Vandyke, Seiji Fukumoto

  29. Suppression of PDGF-induced PI3 kinase activity by imatinib promotes adipogenesis and adiponectin secretion

    Article • March 2012, Bioscientifica

    Kate Vandyke

  30. The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation

    Article • Blood Cancer Journal, February 2011, Springer Science + Business Media

    Kate Vandyke

  31. Plasma Adiponectin Levels Are Markedly Elevated in Imatinib-Treated Chronic Myeloid Leukemia (CML) Patients: A Mechanism for Improved Insulin Sensitivity in Type 2 Diabetic CML Patients?

    Article • The Journal of Clinical Endocrinology & Metabolism, August 2010, Endocrine Society

    Kate Vandyke

  32. The tyrosine kinase inhibitor dasatinib dysregulates bone remodeling through inhibition of osteoclasts in vivo

    Article • Journal of Bone and Mineral Research, March 2010, Wiley

    Natalie A Sims, Kate Vandyke

  33. Dysregulation of bone remodeling by imatinib mesylate

    Article • Blood, November 2009, American Society of Hematology

    Kate Vandyke

  34. Imatinib mesylate causes growth plate closure in vivo

    Article • Leukemia, July 2009, Springer Science + Business Media

    Kate Vandyke

  35. Therapeutic concentrations of dasatinib inhibit in vitro osteoclastogenesis

    Article • Leukemia, December 2008, Springer Science + Business Media

    Kate Vandyke

  36. Plant-Derived MINA-05 Inhibits Human Prostate Cancer Proliferation In Vitro and Lymph Node Spread In Vivo

    Article • Neoplasia, April 2007, Elsevier

    Kate Vandyke

  37. Androgen decreases osteoprotegerin expression in prostate cancer cells

    Article • Prostate Cancer and Prostatic Diseases, December 2006, Springer Science + Business Media

    Kate Vandyke